Introduction
Transcriptomic data have been used extensively in cancer tissues both to sub-type the tumour (14-16) and to 48 predict response to therapies (17, 18) . In contrast in this study we have used peripheral blood gene expression 49 profiling as the source for gene expression profiles, and show that these patterns can be used to predict 50 response to r-hGH in each year of treatment up to five years in two different growth disorders that account
51
for approximately 60% of GH prescriptions. Figure   86 4). We also examined classification of growth response using random forest (RF) with oversampling by SMOTE 87 to correct for uneven class size (GHD, Supplemental Table S3A and TS, Supplemental Table S3B ). These data
88
show clear classification of good and poor responders: at each year of the study all PLS-DA area under the 89 curve of the receiver operating characteristics (AUCs) were between 73% and 98% and all RF AUCs were 90 between 78% and 98% in both conditions.
92
Interactome network models of response to r-hGH
93
There was limited overlap between GHD and TS whole blood transcriptomic markers related to growth 94 response at each year of the study (Supplemental Table S2 ). We therefore generated interactome network 95 models including inferred interactions to assess whether GHD and TS growth response-associated gene 96 expression was related by affecting the function of similar network modules, albeit in different ways.
97
Interactome network models of gene expression associated with height velocity at each year of the study were 98 generated. The hierarchy of overlapping modules of genes was identified in each network using the network 99 topology parameter of "centrality" (Supplemental Table S4 ). Network centrality is measurement that is known 100 to be related to gene function within networks; the more central a gene is, the more capable it is of influencing 101 other genes within the network (20).
The gene level summary of SNP associations with change in height and height velocity measurements with (years 4 and 5) response to r-hGH as would be expected clinically.
116
The facts that i) genetic associations with growth response map to the network models derived from 117 transcriptomic data and that ii) the network connectivity of the central modules changes over the duration of 118 the study imply that the network models are robust and account for the effect of development on related 119 phenotype (Supplemental Table S5 ).
121
The Identification of core sets of genes that can classify response to r-hGH in both GHD and TS
122
The overlap between network models was used to select a common set of genes at each year of therapy 123 present in both GHD and TS. Genes within this common list were selected for growth response classification Table S2 ).
126
Classification of both high and low r-hGH response quartiles against the remaining patients was shown using
We took the core sets of genes previously identified as classifiers of response to r-hGH in both GHD and TS
143
and mapped gene level methylation present in the six GHD patients with knemometry measurements. The 144 majority of genes (57/71) were correlated with growth response (|R|>0.3) these were evenly distributed 145 between positive (n=27/71) and negative (n=30/71) correlations (year one data shown in Figure 8B ).
147
Transcriptomic markers combined with phenotype lead to better growth response prediction an average of 7% (p=0.0031) and 4% (p=0.0365) (prediction of low quartile) along with 4% (p=0.0179) and 4%
151
(p=0.0097) (prediction of high quartile) in GHD and TS respectively (Table S8) .
152
Importantly we also noted a significant decrease of error rate in the prediction of growth response at each 153 year when blood transcriptome markers were combined with clinical phenotype markers. Error rates This study aimed to identify for the first time the genomic associations that classify response to r-hGH therapy 161 from one year up to five years of treatment with r-hGH in children with TS and GHD.
162
Our previous analysis has shown limited utility of genetic associations derived from a candidate set of growth 163 related genes in the prediction of response to r-hGh in GHD and TS after one year of therapy (5, 7, 25) . Hence 164 genetic data do not appear to be powerful enough on their own to be used in prediction and clinical 165 management.
166
The whole blood transcriptomic profile of GHD and TS patients has been shown to be associated with first year 167 growth response to r-hGH (7) and to correlate with the interaction between GHRd3 and GHD severity (25). We 168 therefore reasoned that there may be value in using transcriptomic data to classify growth response, as it 169 reflects both a child's genetic profile and the complex clinical phenotypes arising from changes in physical 170 development during childhood, as well as variation in the severity of the underlying condition. By normalising 171 gene expression for phenotype, including pubertal stage, we were able to show that whole blood 172 transcriptomic data, associated with height velocity at each year of the study, could be used to classify both 173 the low and high quartiles of growth response, with 'Area under the Curve' up to 97%, providing the basis for 174 a predictive test.
175
Little overlap between GHD and TS was observed between the gene expression data that was associated with 176 each year of growth response. We therefore investigated whether GHD and TS were interacting with similar functional units of genes using network models (26). We generated network models of growth response (as 178 determined by height velocity) at each of the five years of treatment using baseline gene expression.
179
Functional modules of genes within these models were ranked according to their network centrality. The to define the functional hierarchy of the modules of genes whose expression was linked to r-hGH response at 182 each year of therapy.
genes were present (INPPL1 and SOS1 in GHD and PTPN1 in TS) out of the four genes identified within the
188
PREDICT validation study as having replicated an association with first year growth response when controlled 189 for co-variates (5).
190
A significant overlap between the core network gene modules between GHD and TS was identified. We then 191 used gene expression changes associated with growth response within these network elements to identify 192 genes common to both conditions and show that their expression could be used to classify growth response.
193
The major strength of this study is to have identified predictive markers and common genomic mechanisms 
199
In this study we have compared the use of baseline patient auxology to blood transcriptome in predicting 200 response to r-hGH. Linear models based on baseline patient auxology can account for ~40-60% of the variance 201 observed (9, 10). Using random forest we found no significant difference in the AUC of baseline auxology alone 202 compared to using blood transcriptome alone in either GHD or TS (all ~90%). It should be noted that this
203
comparison was with the transcriptome shared between GHD and TS and if the full blood transcriptome is 204 used then the average AUC is significantly higher than that derived from baseline auxology (average AUC ~90% 205 compared to ~95%). We recognise that further work would need to be done to refine a smaller number of 206 genes and therefore minimise the risk of overfitting when using the full blood transcriptome. However, we did identify a significant boost to prediction of between 4% and 7% when the transcriptomic signature shared 208 between GHD and TS was combined with the baseline patient auxology. Importantly the gain in prediction was 209 combined with an average halving of the error rate, a feature that represents a major clinical advance in the 210 prediction of response to r-hGH.
211
This work has led to three novel findings relevant to growth studies, and potentially to other therapeutic areas 212 in paediatrics. First, this study has demonstrated the utility of whole blood transcriptome in the classification 213 of growth response in GHD and TS, derived from a baseline blood sample which is straightforward to obtain 214 in any child. This technique may be of particular use in conditions with marked variability in response to r-hGH 215 such as the short child born small for gestational age. Second, network analysis provides a novel approach that 216 can be used to identify genomic features that are likely to have high predictive value. Finally, a set of common 217 genes in GHD and TS identified by a network approach can be used to classify growth response in both 
252
A Kruskal-Wallis rank sum test was applied on the following 3 genetic models a) genotypic (AA, AB, BB); b) 253 dominant (AA/AB+BB) and; c) recessive (AA+AB/BB). For non-pseudoautosomal X chromosome markers, GHD 254 boys and TS girls were analysed as having only two homozygote categories (AA/BB). Adjustment for multiple 255 testing was performed using Bonferroni correction with 2 different parameters as the number of independent 256 tests, the number of Linkage Disequilibrium (LD) blocks in the gene in which the SNP is contained and the total 257 number of LD blocks present in all genes (768 in GHD and 563 in TS). Filtering criterion for prediction were Explorer 2.3 (Qlucore, Lund, Sweden). The data set generated was subject to quality control to investigate the 265 presence of outliers and further confounding effects.
266
Baseline gene expression associations with height velocity in each year of growth response were determined 267 using rank regression with microarray batch, age, body mass index (BMI) at baseline as covariates for both 268 GHD and TS patients along with gender and peak GH test response (average of two provocative tests) for the 269 GHD patients. Over the study a number of children either entered puberty spontaneously or received 270 exogenous sex steroids for pubertal induction. We therefore introduced a further normalisation for Tanner
271
stage to the analysis to account for the proportion of children entering puberty in each year of the study.
273

Generation of network models
274
Network analysis allows the identification and prioritisation of key functional elements within interactome 275 models. To derive an interactome model differentially expressed genes were used as "seeds" and all known 276 protein:protein interactions between the seeds and their inferred immediate neighbours were calculated to 277 generate a biological network using the output of the Biogrid model of the human Interactome (3.3.122)(32).
278
Network generation and processing was performed using Cytoscape 2.8.3(33).
280
Analysis of Gene Network Models
281
Clustering and "community structure" of modules within biological networks arise from variation in 282 connectivity within the network and are known to be associated with function (27, 34) . To rank these 283 functional components within interactome models we used the ModuLand plugin for Cytoscape 2.8.3 to 284 determine overlapping modules and to identify hierarchical structure using the centrality property thus to assess the integrity and connectivity of gene modules (37).
291
Analysis of epigenomic data
292
Epigenomic data from the whole genome DNA previously published methylation profiles of six GHD patients 293 was used to assess the relationship of changes in DNA methylation in relation to response to r-hGH (21). The 294 data from GSE57107 was re-analysed in Qlucore Omics Explorer 3.3 and a median based gene level summary
295
of methylation was determined (n=20618). The relationship between gene level DNA methylation and 296 response to r-hGH was determined using rank regression.
298
Classification of Growth Response
299
All analysis was performed using the statistical software R 3.3.2 (38) 
302
(PLS-DA) (mixOmics 6.1.1 R package (40)) and random forest with 1000 trees (41). Class size imbalance was 303 corrected for using Synthetic Minority Oversampling Technique (SMOTE) (42). Feature selection from random 304 forest data was performed using the BORUTA algorithm (43). The area under the curve of the receiver 305 operating characteristic (AUC) was used to present the probability of a randomly selected sample being 306 classified correctly.
307
In random forests about one third of the cases are left out of each iteration and can be used as a test set to 308 perform cross-validation and to get an unbiased estimate of the test set error, the out of bag (oob) error clinical phenotype alone and these data were then compared to baseline clinical phenotype in addition to 315 blood transcriptomic markers.
317
Statistics
318
Analyses were performed to determine genetic associations with response to r-hGH using the Kruskal-Wallis 319 rank-sum test with Bonferroni corrections for false discovery rate (FDR).
320
Transcriptomic data was subjected to dimensional scaling using Principal Components Analysis (PCA) and Iso-321 map multidimensional scaling (MDS) (44) and used to demonstrate data homogeneity (Qlucore Omics Explorer 322 3.3) along with outliers using cross-validation. Unsupervised analysis of transcriptome data was performed 323 using a projection score to select optimal variable subsets by variance filtering (45).
324
Transcriptomic associations with response to r-hGH were performed using rank regression (p<0.01) and 325 modified for the listed covariates. This was done by fitting a linear model with the factors to be eliminated as 326 predictors, and retaining only the residuals (i.e. subtracting the part explained by the predictors). When a 327 nominal factor was used as covariate (such as gender), this is equivalent to mean-centring each variable over 328 each subgroup defined by the factor.
329
The significance of gene set overlaps derived from the network analysis was determined using the 330 hypergeometric test. Analyses were performed in the stated software or using R (38) .
332
Study approval.
333
The PREDICT (NCT00256126) and PREDICT long-term follow-up (NCT00699855) studies were approved by the long-term response to recombinant human growth hormone in Turner syndrome: development and validation 39.
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Data
503
All transcriptomic data will be available from Gene Expression Omnibus (GEO) and is currently in submission.
504
Most of the GHD patient transcriptomic data is already available from GEO -GSE72439. 
Clinical Characteristics GHD (N=70) TS (N=43)
576
Similarity between samples is represented by their proximity. The star plot shows sample distance from the 577 centroid, the arithmetic mean position of all the points in each group. 
580
Interactome models were generated from the gene expression associated (p<0.01) with the height velocity at A) Similarities in the interactome models of the response of GHD and TS to r-hGH were identified by overlap at each year of therapy. Genes were selected that were significantly related to growth response in either or both GHD and TS. The genes related to each year of therapy were combined into a set of 58 uniquely identified genes and this set was used to generate an interactome module (Reactome plugin for Cytoscape 3.6.0). Genes with a dark border also have a genetic association with growth response in either GHD or TS. Connecting lines represent known protein:protein interactions, size of the node is proportional to the number of connections made.
B) The clustering coefficient of the group of genes in the network module associated with each year of therapy was determined and presented as a histogram (average ± standard error of the mean). The clustering coefficient measures the tendency of nodes to cluster together within a network.
C) The correlation coefficient linking gene expression with growth response at each year of therapy was mapped to the network model, red = positive correlation, green = negative correlation. Genes with a thick border also have a genetic association with growth response in either GHD or TS. 
622
Similarities in the interactome models of the response of GHD and TS to r-hGH were identified by overlap at 623 each year of therapy. Genes were selected that were significantly related to growth response in either or both
624
GHD and TS, generating an identical set of gene probesets used for prediction of both high and low response 625 in both GHD and TS. BORUTA, an all relevant feature selection wrapper random forest based algorithm, was 626 used to confirm the importance of gene expression probe-sets used for classification of response to r-hGH.
627
The BORUTA algorithm uses a 100-fold permutation to define the noise present in the data; the noise is 
645
4 days of r-hGH therapy measured by knemometry were available from previously published data (GSE57107).
646
A gene level summary of DNA methylation was conducted using median values in Qlucore Omics Explorer 
